Clinical trials: Dermatitis, Atopic
Dermatitis, Atopic
Evaluate the Safety, Tolerability of BAT6026
This is a Phase IB/IIA clinical study of BAT6026 in patients with AD. The subjects were adults with moderate to severe atopic dermatitis (AD) whose disease was not adequately controlled by prior topical medications or for which…
- Trial name
- NCT06094179
- Testing
- Monoclonal antibody BAT6026, sodium chloride injection
- Where
- China
- Volunteers
- 33 people
- Sponsor
- Bio-Thera Solutions
Atopic Dermatitis
Phase 1 Study of QX-4533 in Healthy Volunteers and Patients With Moderate-to-Severe Atopic Dermatitis
The goal of this clinical trial is to evaluate the safety and tolerability of QX-453, an investigational treatment, in healthy Chinese volunteers and patients with moderate-to-severe atopic dermatitis.
- Trial name
- NCT07800104
- Testing
- QX4533
- Where
- China
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- QuantX Biosciences, Inc.
Atopic Dermatitis, Healthy Participants
A Study of BYN-001 in Healthy Adults and in Adults With Moderate to Severe Atopic Dermatitis
This first-in-human study evaluates BYN-001, a humanized IgG1 monoclonal antibody targeting interleukin-25 (IL-25), a cytokine implicated in atopic dermatitis.
- Trial name
- BYN-001-101 (NCT07746817)
- Testing
- BYN-001
- Where
- Australia
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Bionyra Pharma
Atopic Dermatitis (AD)
A Study of JYP0066 Cream in Mild-to-Moderate Atopic Dermatitis
This is a Phase 2 research study testing an investigational topical cream called JYP0066 for the treatment of mild-to-moderate atopic dermatitis (eczema) in teenagers (12-17 years old) and adults.
- Trial name
- NCT07843290
- Testing
- JYP0066 4% topical cream, 3% JYP0066 topical cream, 2% JYP0066 topical cream
- Volunteers
- 160 people
- Sponsor
- Guangzhou JOYO Pharma Co., Ltd
Atopic Dermatitis
A Study of BBT001 in Healthy Volunteers (HVs) and in Adult Patients With Atopic Dermatitis (AD)
This is a Phase 1, randomized, blinded, placebo controlled, single-ascending dose (SAD) and multiple-ascending dose (MAD) study of BBT001 in healthy volunteers (HVs) and adult patients with moderate to severe Atopic Dermatitis…
- Trial name
- NCT06808477
- Testing
- BBT001
- Where
- 14 sites in United States, Australia and 2 more
- Volunteers
- 237 people, healthy volunteers welcome
- Sponsor
- Bambusa Therapeutics
Atopic Dermatitis, Atopic
ATI-045 Versus Placebo in Patients With Moderate-to-Severe Atopic Dermatitis
This study evaluates ATI-045 versus placebo in patients with Moderate-to-Severe Atopic Dermatitis.
- Conditions
- Atopic Dermatitis, Atopic, Dermatitis, AD
- Trial name
- NCT07011706
- Testing
- ATI-045
- Where
- 60 sites in United States, Canada
- Volunteers
- 110 people
- Sponsor
- Aclaris Therapeutics, Inc.
Atopic Dermatitis
This Study is a Non-interventional Disease Registry of Adolescent and Adult Patients With Atopic Dermatitis Who Initiate or Switch Any Systemic Treatment
The objectives of this prospective non-interventional study are to characterize the existing unmet needs across the spectrum of atopic dermatitis (AD), enhance the understanding of the patient journey, and evaluate the safety and…
- Trial name
- ARMADA-AD (NCT07290803)
- Where
- 82 sites in United States, Canada and 7 more
- Volunteers
- 1,000 people
- Sponsor
- Sanofi
Adverse Pregnancy Outcomes, Atopic Dermatitis
An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis (AD)
The objective of this study is to describe and compare the incidence of adverse pregnancy outcomes (spontaneous abortion/miscarriage, stillbirth) and prevalence of adverse infant outcomes (major congenital malformations [MCMs]…
- Trial name
- NCT03936335
- Testing
- dupilumab
- Where
- United States
- Volunteers
- 12,343 people
- Sponsor
- Regeneron Pharmaceuticals
Atopic Dermatitis
French Prospective Observational Study in Patients Eligible for Systemic Therapy for Atopic Dermatitis (AD)
The objective of the study is to describe the therapeutic management of patients more than or equal to 18 years old eligible for systemic therapy or treated by systemic therapy for atopic dermatitis (AD).
- Trial name
- FRAME (NCT06837454)
- Where
- 61 sites in France
- Volunteers
- 600 people
- Sponsor
- Sanofi
Atopic Dermatitis
Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis
This trial is designed to evaluate multiple compounds in participants with moderate to severe atopic dermatitis (AD).
- Trial name
- NCT06947993
- Testing
- GHZ339
- Where
- 105 sites in United States, Argentina and 15 more
- Volunteers
- 224 people
- Sponsor
- Novartis Pharmaceuticals
Dermatitis, Atopic
A Study of JNJ-95597528 in Participants With Moderate to Severe Atopic Dermatitis
The purpose of this study is to assess how well JNJ-95597528 works compared to placebo in participants with moderate to severe atopic dermatitis (AD).
- Trial name
- READY-AD (NCT07230860)
- Testing
- JNJ-95597528
- Where
- 62 sites in United States, Argentina and 7 more
- Volunteers
- 189 people
- Sponsor
- Janssen Research & Development, LLC
Atopic Dermatitis
A Dose-ranging Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Galvokimig in Adult Study Participants With Atopic Dermatitis
The purpose of the study is to evaluate the dose-response relationship of galvokimig compared with placebo in study participants with moderate-to-severe atopic dermatitis (AtD).
- Trial name
- PossibILity (NCT07277660)
- Testing
- Galvokimig
- Where
- 59 sites in United States, Bulgaria and 7 more
- Volunteers
- 165 people
- Sponsor
- UCB Biopharma SRL
Atopic Dermatitis (AD)
Study of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis
The goal of this clinical trial is to learn about the safety and effectiveness of ENV-294 in adults with moderate to severe atopic dermatitis.
- Trial name
- NCT07298395
- Testing
- ENV-294
- Where
- 32 sites in United States
- Volunteers
- 105 people
- Sponsor
- Enveda Therapeutics
Atopic Dermatitis
Real-world Effectiveness Study of Long-term Treatment With Dupilumab in Participants ≥6 Years With Atopic Dermatitis
This is a Prospective, non-interventional (NIS) observational study in patients (≥6 years) with atopic dermatitis (AD) receiving dupilumab for the prospective evaluation of signs and symptoms, quality of life and disease control.
- Trial name
- PROTYPE2 (NCT06039241)
- Where
- 55 sites in Germany
- Volunteers
- 572 people
- Sponsor
- Sanofi
Atopic Dermatitis (AD)
EFFICACY AND TOLERANCE OF AN EMOLLIENT CREAM IN SKIN OF COLOR
The aim of this study is to evaluate the efficacy and tolerance of a face and body emollient cream in individuals (infants, children, adults) with phototypes IV-VI presenting mild to moderate atopic dermatitis (study under…
- Trial name
- NCT07839897
- Testing
- Emollient cream RV4660B
- Where
- Brazil
- Volunteers
- 59 people
- Sponsor
- Pierre Fabre Dermo Cosmetique
Dermatitis, Atopic, Eczema, Atopic
Evaluation of 611 in Combination With Topical Corticosteroid in Participants With Moderate to Severe Atopic Dermatitis
This is a randomized, double-blind, placebo-controlled, parallel-group study to evaluate the safety and efficacy of 611 when used in combination with topical corticosteroid (TCS) treatment compared with placebo in combination…
- Trial name
- NCT06554847
- Testing
- 611, Topical corticosteroid
- Where
- 3 sites in China
- Volunteers
- 417 people
- Sponsor
- Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Atopic Dermatitis
Abrocitinib Treatment of Atopic Dermatitis in Children 2 to Less Than 6 Years of Age
This clinical study is designed to test how well a medicine called abrocitinib works and how safe it is for young children (ages 2 to under 6) who have moderate-to-severe eczema (also known as atopic dermatitis).Eczema is a skin…
- Trial name
- NCT07823595
- Testing
- Abrocitinib
- Volunteers
- 90 people
- Sponsor
- Pfizer
Mild to Moderate Atopic Dermatitis
A Study to Evaluate the Safety, Tolerability and Pharmacokinetic Properties of IN-A002 Ointment in Healthy Adult Male Volunteers and Mild to Moderate Atopic Dermatitis Patients
This study aims to evaluate the safety, tolerability and pharmacokinetic properties of IN-A002 Ointment in healthy adult male volunteers and mild to moderate atopic dermatitis patients
- Trial name
- NCT05729074
- Where
- South Korea
- Volunteers
- 81 people, healthy volunteers welcome
- Sponsor
- HK inno.N Corporation
Atopic Dermatitis (AD)
EFFICACY AND TOLERANCE OF AN EYELID BALM IN COMBINATION WITH TACROLIMUS 0.1% IN PATIENTS WITH EYELID ATOPIC DERMATITIS
The aim of this study is to evaluate the tolerance and efficacy of a new emollient cream specifically dedicated to the eyelid area when applied in association with tacrolimus 0.1% in subjects suffering from eyelid Atopic…
- Trial name
- NCT07819071
- Testing
- Tested Emollient RV5258A, tacrolimus 0.1%
- Where
- Poland
- Volunteers
- 33 people
- Sponsor
- Pierre Fabre Dermo Cosmetique
Atopic Dermatitis
Phase 2a Study of Efficacy and Safety of OpSCF in Moderate to Severe AD (Atopic Dermatitis)
The purpose of this study is to determine the efficacy and safety of a monoclonal antibody, OpSCF, in the treatment of adults with moderate to severe Atopic Dermatitis (Eczema). OpSCF will be compared to a placebo.
- Trial name
- NCT06101823
- Testing
- OpSCF
- Where
- 22 sites in United States, Canada
- Volunteers
- 50 people
- Sponsor
- Insmed Incorporated